Gastrointestinal Transit Abnormalities Associated With Severe GI Symptoms in Scleroderma
Researchers evaluated the contribution of abnormal GI transit to systemic sclerosis Medsger GI severity scores and/or UCLA GIT 2.0 symptoms.
Researchers evaluated the contribution of abnormal GI transit to systemic sclerosis Medsger GI severity scores and/or UCLA GIT 2.0 symptoms.
The long-term safety and efficacy of tocilizumab in patients with systemic sclerosis were assessed in an open-label study.
A higher neutrophil count predicted worse disease course and higher long-term mortality in patients with systemic sclerosis-related interstitial lung disease.
Researchers evaluated the cellular mechanism of iloprost in reversing vascular dysfunction in scleroderma.
Recent studies have evaluated new approaches to understand the heterogeneity of systemic sclerosis by optimizing disease classification.
Researchers determined whether machine learning could predict stem cell transplant response in severe scleroderma.
Researchers characterized the safety and tolerability of nintedanib and the dose adjustments for adverse events in patients with systemic sclerosis-associated interstitial lung disease.
Researchers identified secular trends associated with systemic sclerosis mortality over 48 years.
In this systematic review, researchers assessed the role of lung ultrasound in the assessment of interstitial lung disease in systemic sclerosis.
Researchers investigated the association between anti-Ro52 antibodies with responses to specific human cytomegalovirus antigens in systemic sclerosis and lupus.